Top Markets
Coin of the day
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
株式のランク #40225
Fusion Antibodies plc operates as a contract research organization (CRO),... Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
株価
$0.1559364
最終同期: 2026-09-18
時価総額
$195.17K
変化(1日)
6.60%
変化(1年)
-30.91%
GB
取引 Fusion Antibodies plc (FAB)

カテゴリー

Fusion Antibodies plc(FAB)の営業利益率
September 2026 時点の営業利益率 TTM: -118.73%
Fusion Antibodies plc の最新の財務報告と株価によると、現在の営業利益率(TTM)は -118.73% です。2024 年末時点では -201.41% でした。
Fusion Antibodies plc の営業利益率の履歴(2013 から 2026)
各年末の営業利益率
営業利益率 変化
2026 (TTM) -118.73% 31.15%
2025 -90.53% -55.05%
2024 -201.41% 106.24%
2023 -97.66% 251.80%
2022 -27.76% -16.16%
2021 -33.11% 15.77%
2020 -28.60% -58.63%
2019 -69.14% -3,080.17%
2018 2.32% -64.90%
2017 6.61% 253.48%
2016 1.87% -117.22%
2015 -10.86% -34.26%
2014 -16.52% -85.86%
2013 -116.84% 0.00%
同業他社の営業利益率
企業 営業利益率 営業利益率の差
38.59% -100.33%
US
28.81% -100.24%
NL
-149.01% -98.74%
US
25.57% -100.22%
AU
0.00% -
CH
企業の営業利益率とは?
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。